[Sjögren syndrome].
Sjögren's syndrome (SS) is a chronic inflammatory disorder of hitherto unknown origin. The characteristic hallmark of SS is focal lymphocytic infiltration and slow destruction of exocrine glands, such as lacrimal and salivary glands. Sicca symptoms and/or recurrent parotid gland swelling are often accompanied by fatigue. Clinically relevant extraglandular manifestations occur in more than 20% of patients with primary SS. The development of malignant B cell lymphoma is the most important complication, which affects about 5% of primary SS patients who are at higher risk to develop malignant B cell lymphoma, both when compared with the general population as well as with patients with SS secondary to other systemic autoimmune disorders. Treatment of sicca symptoms is primarily symptomatic, whereas glucocorticoids, NSAIDs and/or immunosuppressive drugs may be indicated for the treatment of extraglandular manifestations. New therapeutic strategies, such as B cell targeted therapies, are in clinical testing especially for patients with severe organ manifestations.
Hansen
A
A
Interdisziplinäres Sjögren-Zentrum, Park-Klinik Weißensee, Akademisches Lehrkrankenhaus der Charité, Berlin, Deutschland. hansen@park-klinik.com
Dörner
T
T
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000974:Antibodies, Antinuclear / Q000097:blood; D001688:Biological Products / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D003937:Diagnosis, Differential; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007231:Infant, Newborn; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D008297:Male; D011247:Pregnancy; D011296:Prenatal Diagnosis; D011379:Prognosis; D012307:Risk Factors; D012859:Sjogren's Syndrome / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000974:Antibodies, Antinuclear; D001688:Biological Products; D005938:Glucocorticoids; D007166:Immunosuppressive Agents
Lancet Oncol. 2004 Jun;5(6):341-53
15172354
Arthritis Rheum. 2002 Mar;46(3):748-54
11920411
Eur J Clin Invest. 2010 Nov;40(11):1026-36
20629708
Curr Opin Rheumatol. 2005 Sep;17(5):558-65
16093833
Autoimmun Rev. 2010 Jul;9(9):609-14
20452466
Rheumatology (Oxford). 2008 Jun;47 Suppl 3:iii35-7
18504284
Arch Intern Med. 2005 Nov 14;165(20):2337-44
16287762
Arthritis Rheum. 2004 Apr;50(4):1270-6
15077311
Ann Rheum Dis. 2002 Jun;61(6):554-8
12006334
Inflamm Allergy Drug Targets. 2010 Mar;9(1):10-9
19906008
Ann Rheum Dis. 2010 Jun;69(6):1103-9
19561361
Arch Intern Med. 1999 Jan 25;159(2):174-81
9927101
Autoimmun Rev. 2010 Jul;9(9):600-3
20452465
Z Rheumatol. 2010 Feb;69(1):25-31
20013284
Ann Rheum Dis. 2006 Jun;65(6):796-803
16284097
Nat Clin Pract Rheumatol. 2007 Oct;3(10):561-9
17906611
Lupus. 1996 Jun;5 Suppl 1:S28-30
8803907
Arch Intern Med. 2004 Jun 28;164(12):1275-84
15226160
J Clin Pathol. 1968 Sep;21(5):656-60
5697370
Curr Opin Rheumatol. 2009 May;21(3):205-10
19346949
Arthritis Res Ther. 2007;9(4):218
17697366
Lancet. 2005 Jul 23-29;366(9482):321-31
16039337
Rheumatology (Oxford). 2000 Jan;39(1):97-104
10662881
J Interferon Cytokine Res. 1998 Apr;18(4):255-62
9568728
Z Rheumatol. 2010 Feb;69(1):19-24
20013285